Biogen Faces Legal Challenge Over Alleged Anti-Competitive Practices for Multiple Sclerosis Drug Tecfidera

Biogen has been accused of illegally hindering competition for its multiple sclerosis drug Tecfidera by compensating major pharmacy benefit managers to give precedence to the brand over its generic counterparts. This strategy was reportedly part of the company’s effort to transition the market to a different version of the medication. These allegations were made by a multi-employer welfare plan on Friday. For more details, the original report is available on Law360.